MEDPLUS
Medplus Health Services Limited (MEDPLUS) Stock Analysis
Medplus Health Services Limited is an Indian pharmacy retail chain operating stores and online delivery of medicines and wellness products. It combines prescription fulfilment with private labels and diagnostics tie-ups. Store expansion and same-store growth drive performance. It is listed on Indian stock exchanges.
Healthcare › Pharmaceutical Retailers
₹660.20
+0.01% 1W | -19.60% 52W
Market Cap
7.9k CR
P/E Ratio
37.6
52W High
₹1022.2
52W Low
₹645
Div. Yield
0%
Beta
0.5
50 DMA
₹696.8
200 DMA
₹808.5
Profit Margin
2.9%
Inst. Own.
40.8%
📉 CONSOLIDATING DOWN
🛑 HIT RESISTANCE
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,284 | 1,409 | 1,441 | 1,490 | 1,489 | 1,576 | 1,561 | 1,510 | 1,543 | 1,679 | 1,806 | 1,864 | 1,880 |
| Expenses | 1,213 | 1,324 | 1,350 | 1,385 | 1,395 | 1,452 | 1,429 | 1,373 | 1,412 | 1,530 | 1,648 | 1,695 | 1,746 |
| Operating Profit | 71 | 85 | 92 | 106 | 94 | 124 | 133 | 136 | 131 | 149 | 159 | 169 | 133 |
| OPM % | 6% | 6% | 6% | 7% | 6% | 8% | 8% | 9% | 8% | 9% | 9% | 9% | 7% |
| Other Income | 9 | 10 | 10 | 10 | 9 | 12 | 13 | 16 | 15 | 17 | 18 | 21 | 20 |
| Interest | 23 | 24 | 24 | 25 | 25 | 25 | 26 | 27 | 27 | 29 | 31 | 33 | 33 |
| Depreciation | 52 | 55 | 57 | 59 | 60 | 63 | 62 | 64 | 66 | 69 | 73 | 76 | 78 |
| Profit before tax | 5 | 16 | 20 | 32 | 18 | 48 | 57 | 61 | 53 | 69 | 73 | 80 | 42 |
| Tax % | 26% | 12% | 31% | -5% | 19% | 19% | 19% | 16% | 20% | 19% | 21% | 20% | 21% |
| Net Profit | 4 | 15 | 14 | 34 | 14 | 39 | 46 | 51 | 42 | 56 | 58 | 64 | 33 |
| EPS in Rs | 0.32 | 1.22 | 1.15 | 2.79 | 1.20 | 3.24 | 3.83 | 4.29 | 3.54 | 4.63 | 4.82 | 5.33 | 2.76 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,368 | 1,733 | 2,011 | 2,131 | 2,273 | 2,871 | 3,069 | 3,779 | 4,558 | 5,625 | 6,136 | 6,892 | 7,229 |
| Expenses | 1,336 | 1,696 | 1,940 | 2,073 | 2,153 | 2,737 | 2,852 | 3,507 | 4,292 | 5,270 | 5,648 | 6,284 | 6,620 |
| Operating Profit | 32 | 37 | 71 | 58 | 120 | 134 | 217 | 273 | 266 | 355 | 488 | 608 | 610 |
| OPM % | 2.4% | 2.1% | 3.5% | 2.7% | 5% | 4.7% | 7% | 7% | 6% | 6% | 8% | 9% | 8% |
| Other Income | 4 | 8 | 7 | 8 | 11 | 17 | 21 | 31 | 46 | 40 | 48 | 71 | 76 |
| Interest | 14 | 17 | 19 | 28 | 50 | 47 | 55 | 66 | 83 | 96 | 103 | 120 | 126 |
| Depreciation | 9 | 10 | 11 | 12 | 59 | 75 | 88 | 119 | 182 | 224 | 250 | 283 | 295 |
| Profit before tax | 14 | 19 | 48 | 26 | 23 | 29 | 95 | 118 | 47 | 73 | 183 | 275 | 264 |
| Tax % | 46% | 52% | 40% | -65% | 48% | 94% | 34% | 20% | -6% | 11% | 18% | 20% | |
| Net Profit | 7 | 9 | 29 | 42 | 12 | 2 | 63 | 95 | 50 | 66 | 150 | 220 | 210 |
| EPS in Rs | 419.34 | 508.71 | 1,620.57 | 2,080.06 | 585.46 | 107.02 | 1,393.11 | 8.03 | 4.17 | 5.48 | 12.56 | 18.30 | 17.54 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 15.0% | 18.0% | 15.0% |
| Profit CAGR | 66.0% | 28.0% | 37.0% |
Shareholding Pattern
Promoters40.32%
FIIs16.43%
DIIs26.03%
Public17.18%
Promoters40.29%
FIIs16.53%
DIIs26.51%
Public16.60%
Promoters40.29%
FIIs16.83%
DIIs26.58%
Public16.27%
Promoters40.22%
FIIs15.53%
DIIs27.82%
Public16.41%
Promoters40.19%
FIIs14.38%
DIIs29.95%
Public15.45%
Promoters40.43%
FIIs4.48%
DIIs28.16%
Public26.73%
Promoters40.39%
FIIs14.94%
DIIs22.47%
Public22.10%
Promoters40.33%
FIIs15.61%
DIIs26.19%
Public17.82%
Promoters40.22%
FIIs15.53%
DIIs27.82%
Public16.41%
Promoters40.19%
FIIs14.38%
DIIs29.95%
Public15.45%
MEDPLUS
Holdings Analysis
Key strengths & risk signals
61
Overall
71
Fundamental
51
Technical
Risks (4)
LOW MARGIN! 2.9% profit margin - thin profits.
WEAK POSITION! Current price (660.2) is below both moving averages.
WEAK YEAR! Stock declined 19.6% in the last year.
WEAK! Trading at 4.0% of 52W range - near yearly lows.
Strengths (4)
UNDERVALUED! PEG of 0.59 indicates stock is cheap relative to growth.
LOW VOLATILITY! Beta of 0.50 - stable stock, less market risk.
BULLISH SENTIMENT! In last 30 days: 13 up days, 17 down days. Avg volume on up days: 133,777 vs down days: 126,205. Ratio: 1.06x
NEUTRAL! RSI at 40.3 - balanced momentum.
Fundamental & Technical Analysis
61Overall
71Fundamental
51Technical
Fundamental Breakdown
Growth Quality
26/30
Revenue CAGR: 14.7% (GOOD, 11/15). Profit CAGR: 64.0% (EXCELLENT, 15/15).
Profit Margin
2/10
LOW MARGIN! 2.9% profit margin - thin profits.
PEG Valuation
10/10
UNDERVALUED! PEG of 0.59 indicates stock is cheap relative to growth.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
6/10
MODERATE DEBT! D/E of 0.64 - acceptable leverage.
Public Holding
14/20
MODERATE PUBLIC HOLDING! 26.42% public ownership - balanced ownership structure.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
5/10
BEARISH TREND! 50-day average (696.8) is below 200-day average (808.5) - negative signal.
Price Position
2/10
WEAK POSITION! Current price (660.2) is below both moving averages.
Trend Pattern
10/20
Current trend: CONSOLIDATING DOWN
52W Performance
2/10
WEAK YEAR! Stock declined 19.6% in the last year.
Volume Sentiment
20/30
BULLISH SENTIMENT! In last 30 days: 13 up days, 17 down days. Avg volume on up days: 133,777 vs down days: 126,205. Ratio: 1.06x
RSI
3/5
NEUTRAL! RSI at 40.3 - balanced momentum.
52W Range
1/5
WEAK! Trading at 4.0% of 52W range - near yearly lows.
Momentum
3/5
MIXED MOMENTUM! Price growth is inconsistent - 0.0% (1 week), 0.6% (1 month), -21.1% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.50 - stable stock, less market risk.
MEDPLUS
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q4FY262026-07-24 | Concall PDF | |
| Q3FY262026-02-04 | Concall PDF | |
| Q2FY262025-11-06 | Concall PDF |
Peer Comparison
Healthcare · Pharmaceutical Retailers · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MEDPLUS | ₹660.20 | 37.6 | 2.9% | 14.7% | 64.0% | -19.6% | 61 | CONSOLIDATING DOWN | -21.7% | -48.1% | +21.8% | +0.8% |
| HEALTHX | ₹298.00 | – | -1.3% | 8.0% | – | -8.6% | 60 | BREAKOUT | -89.5% | -122.3% | +58.1% | +16.4% |
| SASTASUNDR | ₹282.60 | 34.6 | 2.0% | 8.0% | – | +10.3% | 54 | BREAKDOWN | -181.8% | -1,118.2% | +34.1% | +10.8% |
| ENTERO | ₹1,795.00 | 62.4 | 1.8% | 25.7% | – | +54.3% | 76 | CONSOLIDATING UP | +37.4% | +36.4% | +38.2% | +1.6% |
| AARTIPHARM | ₹846.50 | 37.5 | 10.4% | -2.6% | -3.3% | -8.8% | 58 | BREAKDOWN | +65.4% | +24.5% | +38.7% | -8.0% |
| SUPRIYA | ₹957.10 | 38.8 | 22.7% | 21.2% | 32.5% | +21.3% | 79 | BREAKOUT | -31.0% | -67.7% | +30.7% | -31.4% |
| NEPHROPLUS | ₹751.50 | 88.7 | 8.1% | 33.9% | – | +57.7% | 73 | CONSOLIDATING UP | +35.0% | +5.3% | +23.7% | +6.1% |
| SANOFI | ₹3,077.20 | 21.9 | 17.9% | -12.6% | -19.3% | -38.5% | 52 | BREAKDOWN | +20.1% | -18.6% | +7.7% | -7.3% |
Data from TradeAlone · Updated daily
MEDPLUS News
